BridGene Biosciences: Valuation, Funding & Investors
BridGene Biosciences is a biotechnology company pioneering the discovery and development of innovative small-molecule drugs that target traditionally undruggable targets. Leveraging its proprietary IMTAC(TM) chemoproteomic platform, BridGene screens covalent small molecules against the entire proteome in live cells to identify novel binding sites and drug candidates for high-value targets.
Leadership & Board
- Current Number of Employees
- 31
- Current LinkedIn Followers
- 5,329
Latest Estimated Valuation
- Total Amount Raised
- $28M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $28M
- Latest Funding Round
- Series B
Company Momentum Positive
BridGene Biosciences LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.
Employee Trend
BridGene Biosciences had 31 employees as of October 26, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
BridGene Biosciences had 5,329 followers as of October 26, 2026. The number of followers increased by 4 (0.08%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Oct 16, 2025 | Series B | $28.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Lapam Capital | Series B |
| Bayland Capital | Series B |
| Proxima Ventures | Series B |
| GTJA Investment Group | Series B |
| Grains Valley Venture Capital | Series B |
Similar Companies
A snapshot of private companies similar to BridGene Biosciences, helping you discover and navigate related company profiles.
Related News and Analysis
